QT Vascular and Teleflex Enter Into Asset Purchase and Option Agreement

 

May 24, 2018—QT Vascular Ltd. announced that it has entered into an asset purchase and option agreement with Teleflex Life Sciences Unlimited Company and Teleflex Incorporated. QT Vascular will seek its shareholders' approval of the agreement.

Under the agreement, Teleflex will acquire the non–drug-coated product line and licenses with respect to intellectual property related to the company's non–drug-coated coronary products (including Chocolate XD and Glider). The agreement also provides Teleflex with an option to purchase QT Vascular's drug-coated balloon (DCB) coronary catheter (Chocolate Heart), which is currently under development.

Independently, QT Vascular will continue to develop and market its other products. This includes its differentiated percutaneous transluminal angioplasty DCB (Chocolate Touch) that is being evaluated in a clinical trial, which is currently enrolling patients in 50 centers and is being conducted under a United States investigational device exemption. The company also plans to develop, acquire, and obtain the rights to new products in new fields of use and to engage in research collaboration activities with large multinational partners, stated QT Vascular.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.